Polyrizon (PLRZ) previously announced the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment.

Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...

has started preclinical studies for an intranasal formulation of Naloxone, intended to treat opioid overdoses. Collaborating with Professor Fabio Sonvico from the University of Parma, the studies ...

Polyrizon Ltd., a biotech company based in Raanana, Israel, has announced the start of preclinical studies for its intranasal Naloxone product aimed at treating opioid overdoses. Collaborating ...

These preclinical studies mark a step forward in evaluating Polyrizon’s Trap and Target™ (T&T) platform for the intranasal administration of Naloxone, an opioid antagonist designed to rapidly ...

Naloxone has been a cornerstone in the fight against the opioid epidemic, which has seen a surge in fatalities due to synthetic opioids like fentanyl. The intranasal delivery method of Naloxone ...

These preclinical studies mark a step forward in evaluating Polyrizon's Trap and TargetTM (T&T) platform for the intranasal administration of Naloxone, an opioid antagonist designed to rapidly ...